Navigation Links
Lung Cancer Alliance Again Salutes NCI for its Now Published Work on Lung Cancer Screening Study Which Proved a 20 Percent Mortality Benefit for Those at Risk for Lung Cancer Using CT Scans
Date:6/29/2011

WASHINGTON, June 29, 2011 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) congratulated the National Cancer Institute (NCI) on the publishing of additional and extensive data from its National Lung Screening Trial (NLST) in the New England Journal of Medicine (NEJM).  

The NLST, one of the largest and most expensive clinical trials ever held, was designed to evaluate CT screening compared to chest x-ray as a way to reduce lung cancer deaths, which currently account for nearly a third of all cancer fatalities.

The eight year trial was stopped last November as soon as it became evident that giving CT scans to current and former smokers before they had symptoms could reduce the number of people who died of lung cancer by over 20% as compared to chest x-rays. Screening with chest x-rays, the comparison arm in the NLST and the subject of several previous trials, again failed to show a benefit.

The additional data released by NCI today indicated that few harms resulted from CT screening and the rate of complications from the diagnostic work up was less than 2%.

"Today's publication gives researchers, policy makers, and the public full access to primary findings from the NLST to guide the use of low-dose helical CT scanning by current and former smokers," said Harold Varmus, MD, NCI Director.  

Laurie Fenton Ambrose, LCA President & CEO, thanked NCI for its investment in the trial which, because of the overwhelming number of lung cancer deaths that occur each year, has the potential to bring about the biggest single reduction ever in overall cancer mortality.

Fenton Ambrose said, "With the additional data NCI released today, and with more still being analyzed, along with the data continuing to be generated in on-going lung cancer CT screening research around the world, we can accelerate efforts to insure that this benefit is optimized in a safe, efficient and equitable way to those at risk for lung cancer and help define more clearly who will benefit most from being screened."

Over 53,000 people participated in the NLST trial which focused only on current and former smokers between the ages of 55 and 74. 

Fenton Ambrose continued, "That description fits the majority of new patients currently being diagnosed with lung cancer so it will be extremely important that screening includes aggressive tobacco cessation counseling and reinforcement for those who have already quit," she said.

The NCI paper published today builds upon the initial data announced in November 2010, which LCA hailed as a "seminal moment for the lung cancer community."

"This is a watershed time in the war on cancer," said James L. Mulshine, MD, LCA Board Member, Professor, Department of Internal Medicine, Associate Provost for Research & VP, Rush University Medical Center.  "The United States Preventive Services Task Force (USPSTF) will be reviewing the remarkable results of the NLST trial. This gives us time to conduct a critical dialogue around societal issues with CT-based lung cancer screening and in parallel proceed with measures to ensure those at risk will have access to high quality, efficient and economical screening resources."  

Yesterday, LCA went live with the first website dedicated to guidance for those considering being screened for lung cancer, "Screen for Lung Cancer.org."  

"We want to help people understand that screening is not a simple, one step procedure, but a process that should only be done by experienced teams and credentialed sites," said Fenton Ambrose, noting that the website would be updated as additional refinements to the screening process become available. 

LCA is also urging Congress to approve pilot screening programs around the country that will include a broader, more diverse population than those who participated in the NLST.

Lung Cancer Alliance, www.lungcanceralliance.org, is the only national non-profit dedicated to providing support and advocacy for those living with or at risk for lung cancer.  LCA is committed to reversing decades of stigma and neglect by empowering those with or at risk for lung cancer, elevating awareness and changing health policy.

Follow Lung Cancer Alliance on Facebook: www.facebook.com/lungcanceralliance

Contact: Kay Cofrancesco
kay@lungcanceralliance.org
202-744-1541


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signal Genetics and DiagnoCure Announce a US$13.3M Collaboration for the Commercialization of Previstage™ GCC Colorectal Cancer Staging Test
2. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
3. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
4. Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference
5. Breast Cancer Patients and Families Stand Up To FDA
6. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
7. Life Technologies Consortium to Create New Frontline Diagnostic Utilising DNA Sequencing for Cancer Patients in the U.K.
8. Leaders in Fight Against Cancer Join Historic Initiative to Address Critical Shortage of Clinical Investigators
9. Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
10. TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval
11. Ventana Medical Systems, Inc. Receives FDA Approval for the First Fully Automated Diagnostic Assay for HER2 Gene Status Determination in Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... , April 19, 2017 Global ... This report on the prostate cancer therapeutics market ... global market. Increasing prevalence of prostate cancer, launch ... in the development of new drugs & therapeutic ... cancer drug due to lesser side effects are ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology:
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
(Date:4/28/2017)... ... April 28, 2017 , ... NuevaCare, a leading home ... as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to its ... bookmark and read organized content on topics such as home care (generally) as well ...
(Date:4/27/2017)... ... April 27, 2017 , ... Today, ... based in Denver, Colorado, announced an agreement to create the Jane and Leonard ... of the Jane and Leonard Korman Family Foundation. The collaboration leverages the strengths ...
Breaking Medicine News(10 mins):